Antiviral Drugs - South Africa

South Africa

In South Africa, the revenue in the Antiviral Drugs market is forecasted to reach €118.10m in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 1.03%, leading to a market volume of €124.30m by 2029.
When compared globally, United States is projected to generate the highest revenue in the market, amounting to €28,120.00m in 2024.
South Africa is experiencing a surge in demand for antiviral drugs due to the high prevalence of HIV/AIDS in the country.

Key regions: Brazil, India, Australia, United States, United Kingdom

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The demand for Antiviral Drugs in South Africa has been on the rise in recent years.

Customer preferences: The customer preferences in South Africa for Antiviral Drugs have been driven by the increasing prevalence of viral infections such as HIV/AIDS, hepatitis B, and C. The high rate of these infections has necessitated the need for more effective and accessible treatment options.

Trends in the market: One of the trends in the Antiviral Drugs market in South Africa is the increasing adoption of generic drugs due to their affordability. This has been driven by the government's efforts to make healthcare more accessible to the population. Another trend is the growing popularity of combination therapies, which offer more effective treatment options for viral infections.

Local special circumstances: South Africa is one of the countries with the highest prevalence of HIV/AIDS in the world, with an estimated 7.7 million people living with the virus. This has led to a high demand for Antiviral Drugs in the country. In addition, the country has a high burden of hepatitis B and C infections, which has further increased the demand for these drugs.

Underlying macroeconomic factors: The South African government has been investing in healthcare infrastructure and increasing funding for HIV/AIDS and hepatitis treatment programs. This has led to an increase in the availability of Antiviral Drugs in the country. In addition, the government has implemented policies to encourage local production of generic drugs, which has further increased the availability and affordability of these drugs. The growing middle class in the country has also contributed to the growth of the Antiviral Drugs market, as more people are able to afford healthcare services.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.